Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats

Behavioural Pharmacology

Volumn 21, Issue 3, 2010, Pages 231-240

  Walf, Alicia A ^a   Frye, Cheryl Anne ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

DMBA; Estrogen receptor; Lordosis; Selective estrogen receptor modulator; Tumor

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CARCINOGEN; ESTRADIOL; RALOXIFENE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CARCINOGENESIS; DEPRESSION; FEMALE; FORCED SWIMMING TEST; HORMONAL THERAPY; HYPOPHYSIS; LORDOSIS; MAZE TEST; NONHUMAN; OVARIECTOMY; RAT; TUMOR VOLUME; UTERUS; UTERUS WEIGHT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CARCINOGENS; CELL PROLIFERATION; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ESTRADIOL; ESTROGENS; FEMALE; MAZE LEARNING; NEOPLASMS; OVARIECTOMY; RALOXIFENE; RATS; RATS, LONG-EVANS; REGRESSION ANALYSIS; SEXUAL BEHAVIOR, ANIMAL; SWIMMING; TIME FACTORS; UTERUS;

EID: 77952378742     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833a5cb0     Document Type: Article

References (61)

1. Berendsen HH, Weekers AH, Kloosterboer HJ (2001). Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats. Eur J Pharmacol 419:47-54.
2. Bhavnani BR, Strickler RC (2005). Menopausal hormone therapy. J Obstet Gynaecol Can 27:137-162.
3. Callejo J, Cano A, Medina M, Villaronga M, Gonzalez-Bosquet E, Sabria J, Lailla JM (2005). Hormonal environment in the induction of breast cancer in castrated rats using dimethylbenzanthracene: influence of the presence or absence of ovarian activity and of treatment with estradiol, tibolone, and raloxifene. Menopause 12:601-608.
4. Cheung SY, Yuen MT, Choi HL, Cheng HK, Huang Y, Chen S, Chan FL (2003). An expression study of hormone receptors in spontaneously developed, carcinogen-induced and hormone-induced mammary tumors in female Noble rats. Int J Oncol 22:1383-1395.
5. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, et al. (1995). The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1589
6. Collaborative Group on Hormonal Factors in Breast Cancer (1997). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350:1047-1059.
7. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197.
8. Cyr M, Morissette M, Landry M, Di Paolo T (2001a). Estrogenic activity of tamoxifen and raloxifene on rat brain AMPA receptors. Neuroreport 12:535-539.
9. Cyr M, Thibault C, Morissette M, Landry M, Di Paolo T (2001b). Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain. Neuropsychopharmacology 25: 242-257.
10. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. (1997). Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647.
11. Dickson A, Henriques N (1992). Menopause: the woman's view. London: Quartet Books.
12. Donner N, Handa RJ (2009). Estrogen receptor b regulates the expression of tryptophan-hydroxylase 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei. Neuroscience 163:705-718.
13. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al.; Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645.
14. Frye CA, Walf AA (2002). Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm Behav 41:306-315.
15. Frye CA, Bayon LE, Pursnami NK, Purdy RH (1998). The neurosteroids, progesterone and 3a,5a-THP, enhance sexual motivation, receptivity, and proceptivity in female rats. Brain Res 808:72-83.
16. Fudge MA, Kavaliers M, Baird JP, Ossenkopp KP (2009). Tamoxifen and raloxifene produce conditioned taste avoidance in female rats: a micro-structural analysis of licking patterns. Life Sci 84:282-289.
17. Gibbs RB, Gabor R, Cox T, Johnson DA (2004). Effects of raloxifene and estradiol on hippocampal acetylcholine release and spatial learning in the rat. Psychoneuroendocrinology 29:741-748.
18. Hoyt JA, Fisher LF, Swisher DK, Byrd RA, Francis PC (1998). The selective estrogen receptor modulator, raloxifene: reproductive assessments in adult male rats. Reprod Toxicol 12:223-232.
19. Huggins C (1965). Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Can Res 25:1163-1167.
20. Hughes ZA, Liu F, Platt BJ, Dwyer JM, Pulicicchio CM, Zhang G, et al. (2008). WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. Neuropharmacology 54:1136-1142.
21. Jarkova NB, Martenyi F, Masanauskaite D, Walls EL, Smetnik VP, Pavo I (2002). Mood effect of raloxifene in postmenopausal women. Maturitas 42:71-75.
22. Jensen EV, Jacobson HI, Walf AA, Frye CA (2010). Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol Behav 99:151-162.
23. Jordan VC, Morrow M (1999). Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20:253-278.
24. Karahancer M, Cirpan T, Kanit L, Terek MC, Dikmen Y, Ozsener S (2008). The effects of raloxifen on depression and cognition in ovariectomized rats. Fertil Steril 89:240-242.
25. Katzenellenbogen BS, Katzenellenbogen JA (2002). Biomedicine. Defining the S in SERMs. Science 295:2380-2381.
26. Kokiko ON, Murashov AK, Hoane MR (2006). Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury. Behav Brain Res 170:233-240.
27. Kow LM, Pfaff DW (2004). The membrane actions of estrogens can potentiate their lordosis behavior-facilitating genomic actions. Proc Natl Acad Sci USA 101:12354-12357.
28. Krezel W, Dupont S, Krust A, Chambon P, Chapman PF (2001). Increased anxiety and synaptic plasticity in estrogen receptor beta-deficient mice. Proc Natl Acad Sci USA 98:12278-12282.
29. Leung G, Tsao SW, Wong YC (2003). Sex hormone-induced mammary carcinogenesis in female Noble rats: detection of differentially expressed genes. Breast Cancer Res Treat 77:49-63.
30. Lund KJ (2008). Menopause and the menopausal transition. Med Clin North Am 92:1253-1271.
31. MacGregor JI, Jordan VC (1998). Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50:151-196.
32. Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson I (1999). Breast-cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy. Int J Cancer 81:339-344.
33. Mazzucco CA, Walker HA, Pawluski JL, Lieblich SE, Galea LA (2008). ERa, but not ERb, mediates the expression of sexual behavior in the female rat. Behav Brain Res 191:111-117.
34. Mitlak BH, Cohen FJ (1999). Selective estrogen receptor modulators: a look ahead. Drugs 57:653-663.
35. Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L (2009). Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 151:703-715.
36. Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH (1999). Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24:115-128.
37. O'Neill K, Chen S, Brinton RD (2004). Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 185:63-80. (Pubitemid 38010279)
38. Ogawa S, Eng V, Taylor J, Lubahn DB, Korach KS, Pfaff DW (1998). Roles of estrogen receptor-alpha gene expression in reproduction-related behaviors in female mice. Endocrinology 139:5070-5081.
39. Ohi Y, Yoshida H (1992). Influence of estrogen and progesterone on the induction of mammary carcinomas by 7,12-dimethylbenz(a)anthracene in ovariectomized rats. Virchows Arch B Cell Pathol Incl Mol Pathol 62:365-370.
40. Pfaff D (2005). Hormone-driven mechanisms in the central nervous system facilitate the analysis of mammalian behaviours. J Endocrinol 184: 447-453.
41. Pinilla L, Barreiro ML, Tena-Sempere M, Aguilar E (2002). Raloxifene effects upon the neuronal system controlling sexual receptivity in female rats. Neurosci Lett 329:285-288.
42. Riggs BL, Hartmann LC (2003). Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618-629.
43. Russo J, Russo IH (1996). Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 39:7-20.
44. Russo IH, Koszalka M, Gimotty PA, Russo J (1990). Protective effect of chorionic gonadotropin on DMBA-induced mammary carcinogenesis. Br J Cancer 62:243-247. (Pubitemid 20242443)
45. Stovall DW, Pinkerton JV (2008). Estrogen agonists/antagonists in combination with estrogen for prevention and treatment of menopause-associated signs and symptoms. Womens Health 4:257-268.
46. Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL (2000). Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 96:359-365.
47. Stygar D, Muravitskaya N, Eriksson B, Eriksson H, Sahlin L (2003). Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol 1:40.
48. Takahata M, Ito M, Abe Y, Abumi K, Minami A (2008). The effect of anti-resorptive therapies on bone graft healing in an ovariectomized rat spinal arthrodesis model. Bone 43:1057-1066.
49. Thomsen A, Kolesar JM (2008). Chemoprevention of breast cancer. Am J Health Syst Pharm 65:2221-2228.
50. Utian WH, Janata JW, Barbier S, Rosen AS, Mayer MH, Taylor MB (2004). Effect of raloxifene on quality of life: a prospective study using the Utian quality of life (UQOL) scale. Menopause 11:275-280.
51. Walf AA (2010). Oestrogen receptor b is involved in the actions of oestrogens in the brain for affective behaviour, but not trophic effects in peripheral tissues. J Neuroendocrinol 22:141-151.
52. Walf AA, Frye CA (2005a). Estradiol's effects to reduce anxiety and depressive behavior may be mediated by estradiol dose and restraint stress. Neuropsychopharmacology 30:1288-1301.
53. Walf AA, Frye CA (2005b). ERb-selective estrogen receptor modulators produce antianxiety behavior when administered systemically to ovariectomized rats. Neuropsychopharmacology 30:1598-1609.
54. Walf AA, Frye CA (2006). A review and update of: mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology 31:1097-1111.
55. Walf AA, Frye CA (2007a). The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2:322-328.
56. Walf AA, Frye CA (2007b). Administration of estrogen receptor b-specific selective estrogen receptor modulators to the hippocampus decrease anxiety and depressive behavior of ovariectomized rats. Pharmacol Biochem Behav 86:407-414.
57. Walf AA, Frye CA (2009a). Estradiol enhances sociosexual behavior and augments carcinogen-induced tumorigenesis in ovariectomized rats. AGE 31:221-229.
58. Walf AA, Frye CA (2009b). Effects of two estradiol regimens on anxiety and depressive behaviors and trophic effects in peripheral tissues in a rodent model. Gender Medicine 6:300-311.
59. Wang T, You Q, Huang FS, Xiang H (2009). Recent advances in selective estrogen receptor modulators for breast cancer. Mini Rev Med Chem 9:1191-1201.
60. Wu X, Glinn MA, Ostrowski NL, Su Y, Ni B, Cole HW, et al. (1999). Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransfer-ase activity in ovariectomized rats. Brain Res 847:98-104.
61. Wurz GT, Read KC, Marchisano-Karpman C, Gregg JP, Beckett LA, Yu Q, Degregorio MW (2005). Ospemifene inhibits the growth of dimethylbenzan-thracene- induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol 97:230-240.